Apply for Tarceva (Erlotinib) Copay Assistance Now

Erlotinib (Tarceva) copay assistance refers to a combination of programs that help eligible patients lower their out-of-pocket costs for erlotinib, including copay cards and manufacturer savings programs, independent foundation grants, and patient assistance programs (PAPs). Once enrolled, eligible patients may pay as little as $0 per prescription depending on insurance and program eligibility.

What QuickRx coordinates for you:

• Copay cards / savings programs: for eligible commercially insured patients
• Patient assistance programs: for uninsured or underinsured patients
• Foundation grants: disease-specific support for lung cancer and pancreatic cancer patients
• Insurance navigation: prior authorization and benefits investigation

QuickRx copay assistance services are always 100% free. Call (917) 830-2525 to find out how much you could save on erlotinib.

Eligibility depends on your insurance type, household income, and the specific program. Manufacturer copay cards and savings programs are typically limited to patients with commercial (private) insurance.

How eligibility generally works:

• Commercial insurance: may qualify for copay cards / manufacturer savings programs
• Medicare, Medicaid, TRICARE, or VA: not eligible for manufacturer copay programs by federal law, but may qualify for independent foundation grants or patient assistance programs
• Uninsured: may qualify for patient assistance programs that provide medication at low or no cost

Our patient navigators run a complete benefits investigation and identify every program you qualify for. Call (917) 830-2525 to get started.

No, QuickRx copay assistance services are always 100% FREE to patients. We never charge for helping you enroll in copay cards, patient assistance programs, or foundation grants for erlotinib.

What’s included at no cost:

• Program identification: we research all available erlotinib copay assistance options
• Application support: we complete paperwork and submit applications on your behalf
• Insurance verification: we check your benefits and coverage details
• Prior authorization: we coordinate with your doctor for any required approvals
• Ongoing management: we handle renewals and monitor for new savings opportunities
• Refill coordination: we ensure continuous medication supply without gaps

As a specialty pharmacy, QuickRx is reimbursed through normal pharmacy dispensing — we don’t charge patients separately for copay assistance services. Ready to get started? Call (917) 830-2525.

Yes, Medicare patients have options for reducing erlotinib costs, though they cannot use manufacturer copay cards due to federal anti-kickback regulations. QuickRx helps Medicare patients navigate alternative assistance programs.

Assistance options for Medicare patients:

• Foundation grants: independent charitable foundations like the PAN Foundation, HealthWell Foundation, and Good Days provide grants to help cover medication costs for lung cancer and pancreatic cancer patients
• State pharmaceutical assistance programs (SPAPs): some states offer additional prescription assistance for Medicare beneficiaries
• Medicare Extra Help (LIS): low-income subsidies that reduce Part D costs. Learn more about Medicare prescription drug assistance.
• Patient assistance programs: may provide erlotinib at low or no cost for qualifying patients with limited income

Our patient navigators actively monitor foundation grant openings and help complete applications quickly when funds become available. Call (917) 830-2525 to discuss Medicare assistance options.

Yes. QuickRx Specialty Pharmacy is URAC- and ACHC-accredited and licensed to dispense in all 50 states. We ship erlotinib directly to patients nationwide with secure delivery, alongside full patient navigator support for insurance, prior authorization, and copay assistance coordination.

Call (917) 830-2525 or complete the form on this page to get started.

Erlotinib is a high-cost specialty oncology medication, and the price you pay can vary widely depending on your insurance, the strength prescribed, the pharmacy, and which copay assistance programs you qualify for. Many patients are surprised by the out-of-pocket cost of targeted cancer therapies like erlotinib — but assistance is available, and eligible patients may pay as little as $0.

How QuickRx helps lower your cost:

• Copay cards / savings programs for eligible commercially insured patients
• Patient assistance programs for uninsured and underinsured patients
• Foundation grants for lung cancer and pancreatic cancer patients
• Generic erlotinib, which is FDA-approved and therapeutically equivalent to brand Tarceva

Pricing disclaimer: QuickRx does not set or quote medication prices on this page. Actual costs depend on your insurance plan, dose, pharmacy, and program eligibility. For general retail and cash-price reference information, you can check independent resources such as GoodRx or Drugs.com. For pricing specific to your situation, contact your prescriber’s office, your insurance plan, or call QuickRx.

To find out what you may pay and which programs you qualify for, call (917) 830-2525.

In the United States, erlotinib is now available as a generic medication. The brand-name product Tarceva has been discontinued by its manufacturer. Importantly, this was a business decision — not a result of any concern about the medication’s safety or how well it works.

What this means for you:

• The name to look for: your prescription will be filled as generic erlotinib
• Same active ingredient: generic erlotinib contains the identical active ingredient as brand Tarceva and meets the same FDA standards for quality, strength, and effectiveness
• Same strengths: generic erlotinib is available in 25 mg, 100 mg, and 150 mg tablets
• Widely available: generic erlotinib is supplied by FDA-approved manufacturers to specialty pharmacies across the country

QuickRx dispenses generic erlotinib nationwide and coordinates copay assistance for eligible patients. Call (917) 830-2525 to learn more.

Yes. Generic erlotinib contains the same active ingredient as brand-name Tarceva and must meet the same FDA requirements for bioequivalence, quality, strength, and effectiveness. It works the same way in the body as the brand-name version.

Generic erlotinib is available in 25 mg, 100 mg, and 150 mg tablets. Your oncologist and pharmacist can confirm the appropriate strength for your treatment. Learn more about generic drugs from the FDA.

QuickRx can help identify copay assistance options for generic erlotinib. Call (917) 830-2525.

Erlotinib is FDA-approved to treat certain cancers as a targeted EGFR tyrosine kinase inhibitor.

FDA-approved (labeled) indications:

• Metastatic non–small cell lung cancer (NSCLC): in tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an approved test — as first-line therapy, maintenance treatment, or as second-or-greater-line treatment after progression following at least one prior chemotherapy regimen
• Locally advanced, unresectable, or metastatic pancreatic cancer: as first-line treatment, in combination with gemcitabine

Important limitations of use:

• Use in combination with platinum-based chemotherapy is not recommended
• Safety and efficacy for metastatic NSCLC with EGFR mutations other than exon 19 deletion or exon 21 (L858R) substitution have not been established

Your oncologist determines whether erlotinib is appropriate for your specific diagnosis and tumor characteristics.

Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It reversibly inhibits the tyrosine kinase activity of the EGFR (also called HER1/EGFR). By blocking intracellular phosphorylation, erlotinib prevents downstream signaling that cancer cells rely on to grow and survive, which results in cancer cell death.

Erlotinib has a higher binding affinity for EGFR exon 19 deletion or exon 21 (L858R) mutations than for the normal (wild-type) receptor, which is why EGFR mutation testing is used to identify patients most likely to benefit.

Erlotinib is taken by mouth once daily on an empty stomach — at least 1 hour before or 2 hours after eating. Take it at about the same time each day, exactly as prescribed by your doctor.

Typical dosing by indication (as prescribed):

• Non–small cell lung cancer: 150 mg once daily, until disease progression or unacceptable toxicity
• Pancreatic cancer: 100 mg once daily, in combination with gemcitabine

Important administration notes:

• Empty stomach: food significantly increases how much erlotinib your body absorbs, so it should be taken without food as directed
• Acid-reducing medications: proton pump inhibitors (PPIs) should be avoided if possible. If you take an H2-blocker, erlotinib should be dosed 10 hours after and at least 2 hours before the H2-blocker dose. Separate antacids by several hours.
• Do not adjust your own dose — only your prescriber should change it

QuickRx pharmacists are available to answer questions about taking erlotinib correctly. Call (917) 830-2525.

The most common side effects of erlotinib involve the skin and digestive system. Many people have manageable side effects, but it is important to recognize potential problems early and report them to your healthcare team.

Common side effects (reported in more than 10% of patients):

• Skin rash (very common; an acne-like rash may appear on the face, back, and chest), dry skin, itching, and nail changes (paronychia)
• Diarrhea, decreased appetite, nausea, vomiting, and mouth sores (stomatitis)
• Fatigue and weakness
• Cough and shortness of breath
• Eye effects such as conjunctivitis and dry eye
• Back pain, joint pain, and muscle/skeletal pain
• Chest pain

Serious side effects — get medical help right away:

• Lung/breathing problems: rare but sometimes serious interstitial lung disease (shortness of breath, cough, fever)
• Liver problems: dark urine, yellowing of skin or eyes, severe fatigue, stomach pain
• Severe diarrhea or dehydration
• Severe skin reactions: blistering, peeling, or a reaction suggestive of Stevens-Johnson syndrome
• Eye problems: eye pain, severe irritation, or changes in vision
• Stomach/intestinal perforation, or signs of bleeding (vomiting blood; black, tarry stools)
• Stroke or heart symptoms: chest pain or pressure, weakness on one side, trouble speaking

This is not a complete list. Contact your healthcare provider promptly about any side effects. QuickRx pharmacists are also available at (917) 830-2525.

Erlotinib interacts with many medications and some foods, so tell your doctor and pharmacist about everything you take — including prescription drugs, over-the-counter products, vitamins, and supplements. Erlotinib is processed by the CYP3A4 and CYP1A2 enzyme systems, which is the basis for many of these interactions.

Important interactions to be aware of:

• Grapefruit and grapefruit juice: avoid entirely — they can increase erlotinib levels in your body
• Acid-reducing medications: proton pump inhibitors should be avoided if possible; H2-blockers and antacids require careful dose separation (see “How do I take erlotinib?”)
• Certain antibiotics and antifungals (such as ciprofloxacin and strong CYP3A4 inhibitors) can raise erlotinib levels
• Certain seizure medications and other CYP3A4/CYP1A2 inducers can lower erlotinib levels
• Warfarin: erlotinib may increase its blood-thinning effect; extra INR monitoring may be needed
• Smoking: tobacco smoke can significantly lower erlotinib levels — tell your doctor if you smoke

QuickRx pharmacists review your complete medication list to identify potential interactions. Call (917) 830-2525 to speak with a pharmacist.

Yes. Cigarette smoking can substantially lower the amount of erlotinib in your body, which may make it less effective. For this reason, patients are advised to stop smoking if possible.

If smoking cannot be avoided, the prescriber may adjust the erlotinib dose under careful monitoring — and the dose must be reduced back to the standard starting dose promptly once smoking stops. Never adjust your dose on your own; this should only be done by your prescriber.

Questions about erlotinib and smoking? Call QuickRx at (917) 830-2525.

Your healthcare provider will monitor you regularly while you take erlotinib to check for side effects and ensure the medication is working safely.

Common monitoring includes:

• Liver function tests (transaminases, bilirubin, alkaline phosphatase) — periodically, and more frequently if you have liver impairment
• Kidney function tests and electrolytes — especially if you are at risk for dehydration
• INR / prothrombin time — if you also take warfarin
• EGFR mutation status — for patients with NSCLC, to confirm erlotinib is appropriate
• Eye (ophthalmologic) assessment — a baseline exam may be considered, with reassessment if eye symptoms develop
• Hepatitis B screening — recommended before starting systemic anticancer therapy

Report any new symptoms between visits — signs of infection, breathing problems, severe diarrhea, severe fatigue, or vision changes. Questions about monitoring? Call (917) 830-2525.

Erlotinib may cause harm to an unborn baby and is generally not recommended during pregnancy. Discuss family planning with your healthcare team before starting treatment.

Important information:

• Contraception: patients who could become pregnant should use effective contraception during treatment and for at least 1 month after the last erlotinib dose
• Pregnancy: based on its mechanism and animal data, erlotinib may cause fetal harm; erlotinib is known to cross the placenta
• Breastfeeding: it is not known whether erlotinib passes into breast milk. Because of the potential for serious side effects in a breastfed infant, patients should not breastfeed during treatment and for 2 weeks after the final dose

Always discuss pregnancy, contraception, and breastfeeding with your oncologist before and during erlotinib treatment.

Store erlotinib at room temperature, 77°F (25°C), with brief excursions permitted between 59°F and 86°F (15°C to 30°C). Keep it in its original container, away from excess heat and moisture, and out of reach of children and pets.

Erlotinib is considered a hazardous drug and should be handled with appropriate care. Do not crush or split tablets unless specifically directed. If you have any unused medication, ask your pharmacist about proper disposal — learn more about safe medication disposal from the FDA.

Questions about storing your erlotinib? Call QuickRx at (917) 830-2525.

QuickRx Specialty Pharmacy combines expert specialty pharmacy services with dedicated copay assistance support for patients taking erlotinib.

What sets QuickRx apart:

• Free copay assistance: we never charge for enrollment in savings programs
• Dedicated patient navigators: work with the same team that knows your situation
• Expert pharmacists: specialized in oncology and specialty medications
• Nationwide home delivery: licensed in all 50 states, URAC- and ACHC-accredited
• Refill coordination: we proactively manage your prescription to prevent gaps in therapy
• Insurance advocacy: we handle prior authorizations and insurance issues on your behalf

Ready to get started? Call (917) 830-2525 to speak with a patient navigator today.